Alkylresorcinols as a New Type of Gut Microbiota Regulators Influencing Immune Therapy Efficiency in Lung Cancer Treatment

Figure 5

AR dynamics in faeces before and after anti-PD 1/PD L1 therapy observed in four groups of patients with lung cancer, with positive, stable, non-negative (positive + stable), and negative dynamics: (a) a common representation of AR dynamics; (b) dynamics of C2 (ethylresorcinol) amounts in different groups of patients according to paired Wilcoxon test ().

(a)

(b)